GGrantIndex
← Leaderboards

David Elihu Greenberg

Ut Southwestern Medical Center

Google Scholar ↗PubMed ↗ORCID ↗
$10,844,872
Attributed
$13,461,568
Total exposure
10
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.8M · FY2012–25
$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,461,568 · 10

By mechanism

R01$5,712,537 · 1
R33$3,549,905 · 3
R21$1,439,839 · 4
U01$1,416,717 · 1
R44$1,342,570 · 1

Top collaborators

Most similar at Ut Southwestern Medical Center

Same institution · by research overlap

Others in their field

Top investigators on “Antimicrobial”

Research focus

AntimicrobialAntibiotic ResistanceAntibioticsPathogenResistanceIn VivoPharmaceutical PreparationsIn VitroMorbidity - Disease RateInfectionLeadAnti-Bacterial AgentsGenesEssential GenesPeptidesGene TargetingMulti-Drug ResistancePhosphorodiamidate Morpholino OligomerGene SilencingPseudomonas AeruginosaResistance MechanismOrganismTechnologyDesign

Grant awards (26)

Identifying Mechanisms of Resistance to Pathogen-Specific Antibacterial Antisense Compounds and Strategies to Circumvent Them$254,478
R21 · FY2025 · AI · contact PI
Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa$1,195,983
R01 · FY2024 · AI · contact PI
Antibiotic Resistance Determination Utilizing Machine Learning$478,747
U01 · FY2024 · AI
Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa$1,125,531
R01 · FY2023 · AI · contact PI
Antibiotic Resistance Determination Utilizing Machine Learning$478,747
U01 · FY2023 · AI
Antibiotic Resistance Determination Utilizing Machine Learning$459,223
U01 · FY2022 · AI
Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa$1,057,733
R01 · FY2021 · AI · contact PI
Noninvasive Treatment of Biofilm on Metallic Implants$759,212
R44 · FY2021 · AI
Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa$1,128,851
R01 · FY2020 · AI · contact PI
Noninvasive Treatment of Biofilm on Metallic Implants$583,358
R44 · FY2020 · AI
Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa$1,204,439
R01 · FY2019 · AI · contact PI
Circumventing Antibiotic Resistance with Novel Gene-Silencing Therapeutics$438,783
R33 · FY2018 · AI · contact PI
Circumventing Antibiotic Resistance with Novel Gene-Silencing Therapeutics$443,512
R33 · FY2017 · AI · contact PI
Gene silencing therapeutics for chronic infections in cystic fibrosis$360,766
R33 · FY2017 · AI · contact PI
Circumventing Antibiotic Resistance with Novel Gene-Silencing Therapeutics$474,777
R33 · FY2016 · AI · contact PI
Gene silencing therapeutics for chronic infections in cystic fibrosis$366,879
R33 · FY2016 · AI · contact PI
Novel gene-silencing therapeutics for multidrug-resistant gram-negative pathogens$359,681
R33 · FY2016 · AI · contact PI
Gene silencing therapeutics for chronic infections in cystic fibrosis$367,923
R33 · FY2015 · AI · contact PI
Novel gene-silencing therapeutics for multidrug-resistant gram-negative pathogens$365,500
R33 · FY2015 · AI · contact PI
Circumventing Antibiotic Resistance with Novel Gene-Silencing Therapeutics$199,973
R21 · FY2015 · AI · contact PI
Novel gene-silencing therapeutics for multidrug-resistant gram-negative pathogens$372,084
R33 · FY2014 · AI · contact PI
Circumventing Antibiotic Resistance with Novel Gene-Silencing Therapeutics$215,059
R21 · FY2014 · AI · contact PI
Gene silencing therapeutics for chronic infections in cystic fibrosis$168,125
R21 · FY2014 · AI · contact PI
Gene silencing therapeutics for chronic infections in cystic fibrosis$248,343
R21 · FY2013 · AI · contact PI
Novel gene-silencing therapeutics for multidrug-resistant gram-negative pathogens$167,728
R21 · FY2013 · AI · contact PI
Novel gene-silencing therapeutics for multidrug-resistant gram-negative pathogens$186,133
R21 · FY2012 · AI · contact PI